Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer

2. september 2020 opdateret af: OncoMed Pharmaceuticals, Inc.

A Phase 1b Study of OMP-305B83 Plus Weekly Paclitaxel in Subjects With Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

The purpose of this study is to test the efficacy and safety of an experimental drug, OMP-305B83, when given in combination with paclitaxel. OMP-305B83 is a humanized monoclonal antibody and was developed to target cancer stem cells. Based on preclinical studies, it is believed that OMP-305B83 may block the growth of cancer stem cells and may also impair the productive growth of new blood vessels, which tumors need to grow and spread.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is an open-label, Phase 1b dose escalation and expansion study of OMP-305B83 plus paclitaxel designed to evaluate the safety, efficacy and pharmacokinetics of OMP-305B83 in combination with paclitaxel in patients with platinum resistant ovarian, primary peritoneal or fallopian tube cancer. This study consists of a screening period, a treatment period and a post-treatment follow up period in which patients will be followed for survival for approximately 12 months. Patients will be enrolled in two stages: a dose-escalation stage and an expansion phase.

Approximately 30 patients will be enrolled in this study at approximately 5 study centers in the United States (U.S)..

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

44

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Forenede Stater
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • University of Colorado, Anschutz Medical Campus
    • Florida
      • Tampa, Florida, Forenede Stater, 33612
        • H. Lee Moffitt Cancer Center & Research Institute, Inc. (Moffitt Cancer Center)
    • North Carolina
      • Charlotte, North Carolina, Forenede Stater, 28204
        • Levine Cancer Institute
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73104
        • Stephenson Cancer Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • The University of Pennsylvania Health System
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37203
        • Tennessee Oncology, PLLC
    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • The University of Texas, MD Anderson Cancer Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

21 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Inclusion Criteria:

  1. Platinum resistant Grade 2 or 3 ovarian, primary peritoneal or fallopian tube cancer
  2. Measureable disease per response evaluation criteria (RECIST) v1.1
  3. Prior bevacizumab
  4. Age > or = 21 years
  5. Adequate organ and marrow function
  6. For women of childbearing potential and men with partners of childbearing potential, agreement (by patient and/or partner) to use two effective forms of contraception from study entry through at least 6 months after the termination visit.
  7. Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  1. Treatment with any anti-cancer therapy, including radiotherapy, chemotherapy, biologic therapy. Prior therapy with weekly paclitaxel for recurrent disease, unless administered more than 2 years prior to enrollment, unless part of an upfront treatment strategy.
  2. History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, clinical signs or symptoms of gastrointestinaI obstruction or other known clinically signification gastrointestinal disease.
  3. Subjects with brain metastases
  4. Subjects with leptomeningial disease or neoplasms in the last 5 years
  5. Blood pressure >140/80
  6. Significant intercurrent illness that will limit the patient's ability to participate in the study
  7. Subjects with known metastases that are currently involving the lumen of the gastrointestinal tract.
  8. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment, or anticipation of need for major surgical procedure during the course of the study
  9. Pregnant or nursing women
  10. New York Heart Association Classification II, III, or IV
  11. Inability to comply with study and follow up procedure

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: OMP-305B83 plus paclitaxel
Medicin: Paclitaxel
administreres intravenøst
Medicin: OMP-305B83
intravenous (in the vein) infusion
Andre navne:
  • bispecifikt monoklonalt antistof

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of dose limiting toxicities (DLT)
Tidsramme: Subjects will be treated and observed for DLT through the end of the first cycle (Days 0-28).
The maximum tolerated dose (MTD) or maximum administered dose (MAD) will be determined in subjects treated with OMP-305B83 in combination with Paclitaxel
Subjects will be treated and observed for DLT through the end of the first cycle (Days 0-28).

Sekundære resultatmål

Resultatmål
Tidsramme
Progressionsfri overlevelse
Tidsramme: Op til 5 år
Op til 5 år
Safety of OMP-30B583 in combination with Paclitaxel will be assessed by adverse event monitoring, physical exams, vital signs, clinical laboratory testing, ECGs, echocardiograms, anti-OMP-305B83 testing, and subject interview on an ongoing basis.
Tidsramme: Through study completion, an average of 6 months
Through study completion, an average of 6 months
To assess Immunogenicity (in terms of formation of anti-drug antibod(ies) against OMP-305B83 in percentage of subjects) of OMP-305B83 in combination with Paclitaxel
Tidsramme: Through study completion, an average of 6 months
Through study completion, an average of 6 months
Response Rate assessed by RECIST criteria 1.1
Tidsramme: At 56 day intervals while on treatment, through study completion, an average of 6 months
At 56 day intervals while on treatment, through study completion, an average of 6 months
Response Rate assessed by CA-125 criteria
Tidsramme: At 28 day intervals while on treatment, through study completion, an average of 6 months
At 28 day intervals while on treatment, through study completion, an average of 6 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

OncoMed Pharmaceuticals, Inc.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. december 2016

Primær færdiggørelse (Faktiske)

1. april 2020

Studieafslutning (Faktiske)

1. april 2020

Datoer for studieregistrering

Først indsendt

13. januar 2017

Først indsendt, der opfyldte QC-kriterier

20. januar 2017

Først opslået (Skøn)

25. januar 2017

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. september 2020

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. september 2020

Sidst verificeret

1. september 2020

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • B83-002

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Paclitaxel

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in New Zealand

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner